Prior to Eli Lilly, she served as Vice President of Clinical Development at Prevail Therapeutics, where she played a pivotal role in designing clinical programs for novel gene therapies targeting ...

Appointment Strengthens Clinical Leadership as VectorY Prepares to Submit Investigational New Drug Application for VTx-002 in ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Dr. Sevigny is a physician-scientist with more than 15 years of leadership in translational and clinical drug development, including as chief medical officer at Prevail Therapeutics, a wholly ...

the company also have active partnerships with Novartis AG (NVS), Caribou Biosciences (CRBU), and Prevail Therapeutics. However, given that, to date, Precision has not announced major changes in ...

Meanwhile, Prevail Therapeutics is developing a gene therapy for a form of Parkinson's that is caused by mutations in the GBA1 gene, and Aspen Neuroscience is working on a personalised stem cell ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need ...

Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last ...

2024 was primarily the result of an increase in revenue recognized under the Prevail agreement as well as new license agreements with TG Therapeutics and Caribou Biosciences in the year ended ...

Our development efforts are complemented by our continued business development focus, and we were very pleased to complete ...